A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Janssen - Cilag International

Participant type

Pediatric, Patients

Age range

0-17 years, 18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Immune System Diseases [C20]

Trial duration

5 Dec 2023 → ongoing

Decision date (initial)

2023-11-28

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy, Therapy, Pharmacokinetic, Others, Pharmacogenomic, Pharmacodynamic

To evaluate the efficacy of JNJ-77242113 in participants with plaque psoriasis with at least moderate severity affecting special areas or lower BSA (range: ≥5% to <10%) moderate to severe plaque psoriasis.

Conditions and MedDRA coding

Plaque Psoriasis

Regulatory references

Scientific advice from competent authorities

European Medicines Agency, Food And Drug Administration

Plan to share IPD

Yes

IPD plan description

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 5

1. 1. ≥12 years of age at the screening visit.
2. 2. Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention.
3. 3. Candidate for phototherapy or systemic treatment for plaque psoriasis.
4. 4. Need to meet criteria (a) and/or (b) a. Total BSA ≥1% at screening and baseline, AND IGA (overall) ≥2 at screening and baseline AND at least one of the following: - ss-IGA score ≥3 at screening and baseline, and/or - sPGA-G ≥3 at screening and baseline, and/or - hf-PGA score ≥3 at screening and baseline.
5. 5. Failed to respond to at least 1 topical therapy used for treatment of psoriasis.

Exclusion criteria 5

1. 1. Nonplaque form of psoriasis.
2. 2. Dermatoses other than plaque psoriasis or palmoplantar pustulosis of the palmoplantar area.
3. 3. Current drug-induced psoriasis.
4. 4. A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
5. 5. Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. IGA (overall) score of 0 or 1 and a ≥2-grade improvement from baseline at Week 16.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen - Cilag International

Sponsor organisation

Janssen - Cilag International

Address

Turnhoutseweg 30

City

Beerse

Postcode

2340

Country

Belgium

Scientific contact point

Organisation

Janssen - Cilag International

Contact name

CTIS Point of Contact

Public contact point

Organisation

Janssen - Cilag International

Contact name

CTIS Point of Contact

Third parties 4

Locations

4 EU/EEA countries · 39 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 91 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

9 submissions — initial application plus substantial / non-substantial modifications